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Abstract
Biomarker analysis for colorectal cancer has been shown to be reliable in Europe with 97% of samples tested by EQA participants
to be correctly classified. This study focuses on errors during the annual EQA assessment. The aim was to explore the causes and
actions related to the observed errors and to provide feedback and assess any improvement between 2016 and 2017. An electronic
survey was sent to all laboratories with minimum one genotyping error or technical failure on ten tumor samples. A workshop
was organized based on 2016 survey responses. Improvement of performance in 2017 was assessed for returning participants
(n = 76), survey respondents (n = 13) and workshop participants (n = 4). Survey respondents and workshop participants improved
in terms of (maximum) analysis score, successful participation, and genotyping errors compared to all returning participants. In
2016, mostly pre- and post-analytical errors (both 25%) were observed caused by unsuitability of the tumor tissue for molecular
analysis. In 2017, most errors were due to analytical problems (50.0%) caused by methodological problems. The most common
actions taken (n = 58) were protocol revisions (34.5%) and staff training (15.5%). In 24.1% of issues identified no action was
performed. Corrective actions were linked to an improved performance, especially if performed by the pathologist. Although
biomarker testing has improved over time, error occurrence at different phases stresses the need for quality improvement
throughout the test process. Participation to quality improvement projects and a close collaboration with the pathologist can
have a positive influence on performance.
Keywords Colorectal cancer .External quality assessment .Molecular pathology .Error analysis .Correctiveactions .Biomarker
analysis
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Abbreviations
BRAF B-Raf proto-oncogene
EGFR Epidermal growth factor receptor
ESP European Society of Pathology
FE Fisher’s exact test
KRAS Kirsten rat sarcoma viral oncogene homolog
mCRC Metastatic colorectal carcinoma
MWU Mann-Whitney U test
NGS Next-generation sequencing
NRAS neuroblastoma rat sarcoma
WT Wild-type
Χ2 Chi-squared test
Introduction
Metastatic colorectal carcinoma (mCRC) is the third most
commonly diagnosed malignancy and the fourth leading
cause of cancer death worldwide [1]. Besides standard che-
motherapy, mCRC patients are currently receiving personal-
ized treatment by anti-epidermal growth factor receptor
(EGFR) monoclonal antibodies, which has been shown to
significantly increase the median survival time from 18.5 to
23.5 months of mCRC patients [2].
In 2008, mutations in exon 2 of the Kirsten rat sarcoma
viral oncogene homolog (KRAS) gene were shown to be a
negative predictor for anti-EGFR therapy benefit [2, 3]. In
2013, the same was demonstrated for mutations in KRAS
exons 3 and 4, and for the less frequent mutations in neuro-
blastoma rat sarcoma (NRAS) viral oncogene homolog exon
2–4 [4, 5], resulting in an extension of the drug labels for
cetuximab and panitumumab by the European Medicine
Agency (EMA) [6, 7]. Consequently, molecular diagnostic
laboratories were challenged to include these new test require-
ments in a correct and timely manner [4].
Since 2009, the European Society of Pathology (ESP) has
been involved in the organization of a yearly colon external
quality assessment (EQA) scheme to assess and improve RAS
biomarker analysis in mCRC [8, 9]. Based on the updated
requirements, the 2013 ESP colon EQA scheme was expand-
ed by the assessment of full RAS testing (exon 2, 3, and 4 of
both KRAS and NRAS) [10]. Since that same year, laboratories
could also optionally test the BRAF (B-Raf proto-oncogene)
gene, which has demonstrated prognostic value and is increas-
ingly being analyzed in Europe [11].
Results from the 2013 scheme revealed that full RAS test-
ing was only implemented by half of the laboratories (49.3%,
n = 131 laboratories) and that there were numerous errors in
testing the new gene segments [10]. In addition, EQA data
confirmed that molecular diagnostic laboratories in Europe
are using a large variation in methods for (a) the estimation
of the neoplastic cell content [12], (b) for DNA extraction
[13], and (c) for determining the RAS and BRAF status [13].
A 2016 study showed that the vast majority of samples
(97%) tested by laboratories participating to an EQA scheme
had been correctly classified. For about 2% of samples tested,
an incorrect outcome was obtained that could potentially lead
to a different anti-EGFR therapy advice [14]. Given the po-
tential impact of predictive biomarker analyses on patient out-
come, it is important to evaluate the exact causes of errors and
to provide tailored feedback to diagnostic laboratories for
quality improvement [15]. In turn, laboratories are encouraged
to implement the necessary corrective and preventive actions
(CAPA) as a required by the ISO15189 standard [16] or na-
tional equivalents, and the Clinical Laboratory Improvement
Amendments of 1988 [17].
In clinical biology and forensics, error causes have been
shown to occur mostly during the pre- (46–86%) and post-
analytical (18–47%) phases of the total test process (TTP)
compared to the analytical phase (7–13%) [18, 19], although
the lack of standardization in taxonomy accounts for some of
the variation seen in these error rates [20].
Although EQA schemes reflect the performance of diag-
nostic laboratories, more detailed information is required on
the error causes and distribution throughout the TTP for mo-
lecular cancer diagnostics, as well as the actions undertaken
by laboratories to improve quality in the long-term [21].
Therefore, the objectives of this study were (a) to evaluate
the causes, distribution, and follow-up of laboratory errors
from laboratories participating to the ESP colon EQA scheme;
(b) to provide feedback to laboratories as to how practice can
be improved, and (c) to assess potential improvement between
2016 and 2017 EQA schemes.
Material and methods
The 2016 and 2017 ESP colon EQA schemes were organized
according to the ISO 17043 standard for proficiency testing
[22] and the guideline on the requirements of external quality
assessment programs in molecular pathology [23].
Participation to EQAwas free of choice and open to all labo-
ratories worldwide. Details on validation, results submission,
and feedback provided to the laboratories have been previous-
ly described ([13], Supplemental Table 1).
At the end of both EQA schemes, all laboratories with at
least one major genotyping error, a score Bi,^ or technical
failure (in which no result could be obtained for a case) in
one of the ten provided formalin-fixed paraffin-embedded
cases were invited by e-mail to complete an electronic survey
with both laboratory-specific (general) questions and case-
specific questions for each observed error. A list of definitions
was included to clarify all questionnaire terms (Supplemental
Table 2). Data was collected for 1 month, laboratories
received a first reminder after 14 days and a second the
day before the deadline.
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All participants to the 2016 EQA scheme were invited to
attend a 1.5-day long optional workshop, organized in
December 2016 at the Radboud University Medical Center,
The Netherlands. Topics were based on the 2016 survey out-
put and included issues occurring in the pre-, post-, and ana-
lytical phase as cited by the survey respondents. A separate
microscopy session focusing on the estimation of neoplastic
cell content was held outside this project (Dufraing et al., sub-
mitted for publication).
Improvement of RAS testing was evaluated between both
ESP colon EQA scheme years on three levels: (a) laboratories
who participated in both schemes, (b) 2016 survey respon-
dents, and (c) participants to the 2016 workshop. For these
three categories, the average genotyping score, percentage of
participants with the maximum score of 20, the percentage of
successful participants, and re-occurrence of genotyping er-
rors and/or technical failures were assessed.
Response bias was assessed by investigating the difference
in laboratory characteristics between survey respondents and
non-responders. Missing data were reported in the tables ac-
cordingly and not included in the statistical analysis. The re-
ported accreditation statuses and laboratory settings were val-
idated on the websites of the relevant national accreditation
bodies and the laboratories’ website, respectively.
Comparison of categorical variables was performed using
chi-squared (Χ2) tests or a Fisher’s exact (FE) test if one of
the row or column cells counted below five. For the difference
in the sample amounts tested and people involved in the lab-
oratory between responders and non-respondents, categories
were treated as ordinal data following a Mann-Whitney U
(MWU) test. For a combination of categorical and continuous
variables (e.g., improvement of the average genotyping score
between more than two groups) a one-way ANOVA with
Tukey’s HSD was performed. Bonferroni corrections were
applied when necessary. The significance level was set at
α = 0.05. All statistical analyses were performed using SPSS
Statistics Subscription version 1.0.0.903 (IBM, Armonk, NY,
USA). Graphs were created using Microsoft Excel
Professional Plus 2013.
Results
ESP Colon EQA scheme results
In the 2016 and 2017 colon EQA schemes, 123 labora-
tories from 27 countries and 105 from 29 countries
participated, respectively. Seventy-six laboratories partic-
ipated in both EQA schemes. They displayed a signifi-
cant correlation between the average genotyping scores
in 2016 and 2017 (Spearman R = 0.29, p = 0.011).
Participants with a genotyping error or the maximum
score in 2016 were more likely to obtain a genotyping
error (p = 0.032) and reach the maximum score (p =
0.022) in 2017.
In 2017, the average genotyping score was 82.5% and the
successful participation according to pre-defined scoring
criteria [23] was 57.1% (60/105). In addition, 45.7% (48/
105) laboratories obtained the maximum score of 20/20. In
2017, the number of participants making a genotyping error
was 41.9% (44/105), whereas the number of participants with
a technical failure was 3 participants (2.9%).
The total number of genotyping errors and technical fail-
ures on sample level is shown in Table 1.
The proportion of samples misclassified was 4.6% (56/
1230) in 2016 and 6.1% (64/1050 samples) in 2017. The
average genotyping score, the number of participants with a
successful participation and the number of technical errors
were lower in the 2017 compared to the 2016 EQA scheme.
The number of genotyping errors were higher in 2017, but not
related to (a) new participants, (b) laboratories who switched
methods, or (c) used a specific method type.
Characteristics of survey respondents
Based on the EQA results, 51 and 49 laboratories received the
survey in 2016 and 2017, respectively. Twenty-two (43.1%)
participants in 2016 and 18 (36.7%) in 2017 responded within
20 days. Data from one survey participant in 2016 was not
taken into account for further analysis, as only one of the
questions was answered. Response rates did not differ depend-
ing on the country, or whether they had completed the previ-
ous (2016) survey.
The laboratory characteristics during the 2016 and 2017
EQA schemes are shown in Table 2. For both schemes most
respondents performed RAS and BRAF analysis in a routine
clinical setting using commercial kits. The majority were not
accredited for molecular analysis and were situated in a uni-
versity or general hospital. For most of the respondents the
analysis was performed under the department of pathology
(61.9% and 88.9% in 2016 and 2017, respectively), and in-
cluded on average between 1 and 10 people. Six (28.6%)
laboratories that participated in the 2016 scheme responded
that the analysis was performed by another laboratory (com-
pared to 0.0% in 2017). Of these, 5 laboratories outsourced the
evaluation of the neoplastic cells, and 1 the DNA extraction
step. For all participants, the estimation of the percentage of
neoplastic cells was performed by a pathologist.
Laboratory characteristics collected during the EQA
scheme for those participating in the survey were compared
to the non-respondents. In 2016, the survey participants were
less likely to have performed the analysis under the pathology
department compared to non-participants. Similarly, the 2016
respondents were more likely to have outsourced the analysis
to another laboratory (Table 2).
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Table 2 Overview of laboratory characteristics for non-survey respondents and survey respondents as obtained during the EQA scheme
2016 2017
# responders
(n = 21°)
# non-responders
(n = 101)
# responders
(n = 18)
# non-responders
(n = 87)
Number of countries 14 26 14 25
Performs test in routine practice
KRAS 20 95.2 96 95.05 17 94.4 82 94.3
NRAS 20 95.2 94 93.07 17 94.4 81 93.1
BRAF 18 85.7 89 88.12 14 77.8 81 93.1
Number of KRAS samples tested in last 12 months
1–99 4 19.0 18 17.82 5 27.8 21 24.1
100–249 8 38.1 43 42.57 5 27.8 35 40.2
250–499 5 23.8 24 23.76 7 38.9 17 19.5
> 500 3 14.3 11 10.89 0 0.0 9 10.3
No clinical testing 1 4.8 5 4.95 1 5.6 5 5.7
Number of NRAS samples tested in last 12 months
1–99 6 28.6 24 23.76 10 55.6 24 27.6
100–249 6 28.6 43 42.57 4 22.2 37 42.5
250–499 5 23.8 21 20.79 3 16.7 15 17.2
> 500 3 14.3 6 5.94 0 0 5 5.7
No clinical testing 1 4.8 7 6.93 1 5.6 6 6.9
Number of BRAF samples tested in last 12 months
1–99 7 33.3 40 39.60 9 50.0 37 42.5
100–249 5 23.8 32 31.68 3 16.7 28 32.2
250–499 4 19.0 12 11.88 2 11.1 13 14.9
> 500 2 9.5 5 4.95 0 0.0 3 3.4
No clinical testing 3 14.3 12 11.88 4 22.2 6 6.9
People involved in the analysis
1–10 16 76.2 91 90.10 16 88.9 78 89.7
11–20 4 19.0 7 6.93 1 5.6 7 8.0
> 20 1 4.8 3 2.97 1 5.6 2 2.3
Laboratory setting
Anti-cancer center 3 14.3 8 7.9 3 16.7 10 11.5
Education and research hospital 0 0.0 1 1 0 0.0 2 2.3
General hospital 8 38.1 26 25.7 5 27.8 25 28.7
Industry 0 0.0 3 3 1 5.6 5 5.7
Private 5 23.8 20 19.8 4 22.2 15 17.2
Private hospital 0 0.0 4 4 0 0.0 2 2.3
University 0 0.0 6 5.9 2 11.1 4 4.6
University hospital 5 23.8 33 32.7 3 16.7 24 27.6
Accreditation status
Accredited 10 47.6 40 39.6 3 16.7 34 39.1
Not accredited 11 52.4 61 60.4 15 83.3 53 60.9
Analysis performed under the department of pathology *Χ2(1) = 12.3, p < 0.001
Yes 13 61.9 92 91.09 16 88.9 71 81.6
No 8 38.1 9 8.91 2 11.1 16 18.4
Part of the analysis performed by another laboratory *Χ2(1) = 3.9, p = 0.05
Yes 6 28.6 12 11.88 0 0.0 12 13.8
No 15 71.4 89 88.12 18 100.0 75 86.2
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Error cause analysis
Responses to the case-specific questions resulted in a total of
35 (2016) and 24 (2017) issues that were further analyzed.
The issues examined in this study comprised 42.9% and
39.1% of the total genotyping errors and 66.7% and 25.0%
of the technical failures observed in the 2016 and 2017 EQA
schemes, respectively. An overview of case-specific and
laboratory-specific answers is given in Table 3.
The majority of the 2016 errors (37.1%) occurred in the
post-analytical phase of the testing process, compared to ana-
lytical problems in 2017 (50.0%). BTissue problems^ caused by
the insuitability of the tumor tissue (e.g., insufficient amount of
neoplastic cells or degradation of the DNA), and methodolog-
ical problems were the most frequent detailed causes. In 2017,
problems were more frequently detected before release of the
final EQA results, and more often no CAPA was undertaken.
Looking at all test phases, only laboratories with an error in the
pre-analytical phase were less likely to obtain a maximum score
in 2017 (p = 0.031). There was no difference in the number of
errors in subsequent test phases and their specific causes com-
pared to genotyping errors, technical failures, successful partic-
ipations, or maximum scores obtained in 2017.
In both years, occurrence throughout the TTP differed sig-
nificantly for different analysis methods (KRAS p = 0.019,
NRAS p = 0.044, BRAF p = 0.006). Analytical and post-
analytical errors occurred more for commercial kits, compared
to pre-analytical errors for non-commercial users. However,
specific error causes and the CAPAs undertaken were not
linked to a certain methodology.
Corrective/preventive actions
On average between 1 and 2 persons were included in carry-
ing out the respective CAPA although errors in 2017 required
more often involvement of the laboratory director compared to
the (lead) technician in 2016 [Table 3]. There was no link
between the phase or cause of the problem and the number
or occupation of persons involved. However, only errors
followed-up by the pathologist, were less likely to result in a
genotyping error in 2017 and were more likely to result in a
successful participation (both p = 0.012).
The most performed CAPAs included protocol revi-
sions (n = 20) and staff trainings (n = 9). The CAPA type
was linked to the cause of the errors, but not to a test
phase [Fig. 1]. For 14 problems, no action was under-
taken at all. Seven of them included problems with the
tissue material [Fig. 1]. In 2016, the type of CAPA was
correlated to less genotyping errors, successful participa-
tion (both p = 0.027), and obtaining the maximum score
(p = 0.045) in the 2017 EQA scheme, especially for pro-
tocol revisions. Time of error registration (before or af-
ter the release of the EQA results) had no influence on
the next scheme’s performance.
At laboratory level, more laboratories changed their meth-
od or protocol in 2016 compared to 2017 (Table 3). In both
years, interpretation as well as reporting of the results was
mainly performed by the molecular biologist and pathologist.
Whereas the pathologist mainly interpreted results of commer-
cial kits, non-commercial methods were mainly interpreted by
the laboratory director.
Table 2 (continued)
2016 2017
# responders
(n = 21°)
# non-responders
(n = 101)
# responders
(n = 18)
# non-responders
(n = 87)
Method KRAS
Commercial kit 10 47.6 49 48.51 11 61.1 40 46.0
NGS 5 23.8 24 23.76 3 16.7 27 31.0
Non-commercial method 6 28.6 28 27.72 4 22.2 20 23.0
Method NRAS
Commercial kit 9 42.9 46 45.54 11 61.1 37 42.5
NGS 5 23.8 24 23.76 3 16.7 27 31.0
Non-commercial method 7 33.3 31 30.69 4 22.2 23 26.4
Method BRAF
Commercial kit 7 33.3 39 38.61 9 50.0 35 40.2
NGS 5 23.8 22 21.78 3 16.7 25 28.7
Non-commercial method 5 23.8 26 25.74 2 11.1 18 20.7
Not performed 4 19.0 14 13.86 4 22.2 9 10.3
No missing data was observed for a specific question unless specified otherwise in the table. °1 laboratory was not included as a survey respondent
because all data was incomplete. *Significant difference. Abbreviations: BRAF: B-Raf proto-oncogene, KRAS: Kirsten rat sarcoma viral oncogene
homolog, NGS: next-generation sequencing, NRAS: neuroblastoma rat sarcoma
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Table 3 Overview of survey responses after the 2016 and 2017 ESP colon EQA scheme
Question 2016 survey respondents 2017 survey respondents
# observations % observations # observations % observations
Case-specific questions
Total number of errors analyzed 35 100.0 24 100.0
Phase in the total testing process
Pre-analytical 12 34.3 6 25.0
Analytical 10 28.6 12 50.0
Post-analytical 13 37.1 6 25.0
Type of problem
Clerical error 6 17.1 2 8.3
Interpretation error 5 14.3 3 12.5
Methodological problem 3 8.6 7 29.2
Personnel error 5 14.3 6 25.0
Problem with the tissue 10 28.6 2 8.3
Reagent problem 2 5.7 0 0.0
Technical problem 3 8.6 4 16.7
Missing data 1 2.9 0 0.0
Detection of the error* FE, p < 0.05
Before release of the EQA results 1 2.9 6 25.0
After release of the EQA results 25 71.4 17 70.8
Missing data 9 25.7 1 4.2
Corrective/preventive actions* Χ2 (9) = 18.6, p < 0.05
Contact manufacturer 2 5.7 5 20.8
None 6 17.1 8 33.3
Optimization/implementation of documents 1 2.9 0 0.0
Protocol revision 15 42.9 5 20.8
Protocol revision + subsequent staff training 0 0.0 2 8.3
Retesting of samples 1 2.9 0 0.0
Staff training 6 17.1 3 12.5
Unknown 3 8.6 0 0.0
Missing data 1 2.9 0 0.0
Change method 0 0.0 1 4.2
Person involved in follow-up° FE, p < 0.05
Lead laboratory technician* 12 34.3 1 4.2
Laboratory technician 9 25.7 5 20.8
Pathologist 10 28.6 5 20.8
Molecular biologist 17 48.6 14 58.3
Quality manager 2 5.7 3 12.5
Laboratory director* 4 11.4 9 37.5
Scientific employee 1 2.9 0 0.0
Medical geneticist 0 0.0 1 4.2
Missing data 5 14.3 0 0.0
Laboratory-specific questions
Total number of laboratories responded 21 100.0 18 100.0
General change of method/protocol based on the EQA results
Yes 12 57.1 4 22.2
No 9 42.9 10 55.6
Maybe 0 0.0 2 11.1
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In case a pathologist was involved in reporting, participants
were more likely to obtain no genotyping errors (p = 0.15), a
higher genotyping score (p = 0.034), the maximum score (p =
0.028), and a successful participation (p = 0.015) in 2017.
This was not the case for the interpretation or reporting
by any of the other responsible persons.
Feedback to laboratories
Ten participants from six laboratories at different countries
(Austria, Germany, Israel, Portugal, Romania, and Turkey)
accepted the invitation to attend the workshop. From those
six institutes who attended, four of them also completed the
Table 3 (continued)
Question 2016 survey respondents 2017 survey respondents
# observations % observations # observations % observations
Missing data 0 0.0 2 11.1
Person involved in interpretation of the results°
Lead laboratory technician 3 14.3 0 0.0
Laboratory technician 8 38.1 6 33.3
Pathologist 8 38.1 6 33.3
Molecular biologist 15 71.4 15 83.3
Molecular biology consultant 0 0.0 1 5.6
Laboratory director 2 9.5 2 11.1
Clinical biologist (MD) 1 4.8 0 0.0
Engineer 1 4.8 0 0.0
Medical geneticist 0 0.0 1 5.6
Training of the personnel involved in interpretation of the result°
By school degree 4 19.0 2 11.1
External: attending workshops 3 14.3 2 11.1
External: training by manufacturer 4 19.0 0 0.0
Internal and external (not specified) 1 4.8 0 0.0
Internal only (not specified) 1 4.8 0 0.0
Internal: exchange with other lab/EQA 1 4.8 0 0.0
Internal: learning from colleagues with gradually more independence 6 28.6 5 27.8
Internal: participation to laboratory meetings 4 19.0 1 5.6
Internal: performing validations 4 19.0 3 16.7
None 3 14.3 0 0.0
Missing data 0 0.0 6 33.3
Person involved in reporting of the results°
Lead laboratory technician 2 9.5 0 0.0
Laboratory technician 2 9.5 4 22.2
Pathologist 10 47.6 6 33.3
Molecular biologist 11 52.4 12 66.7
Quality manager 1 4.8 0 0.0
Laboratory director 3 14.3 3 16.7
Clinical biologist (MD) 1 4.8 0 0.0
Medical geneticist 0 0.0 1 5.6
Administrative staff 0 0.0 1 5.6
Request for retesting the sample* Χ2 (3) = 22.5, p < 0.001
No 1 4.8 4 22.2
Yes, always 6 28.6 4 22.2
Yes for routine practice but not in EQA 1 4.8 10 55.6
Missing data 13 61.9 0 0.0
Nomissing data was observed for a specific question unless specified in the table. °Multiple options could be selected, which is why percentages add up
to more than 100.0%. *Statistical difference
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2016 survey and participated again in the 2017 scheme.
Attendees scored the quality and usefulness for routine imple-
mentation of the workshop at 95 and 89 on 100 points, respec-
tively. Participants responded that the main hurdles to over-
come related to biomarker testing were routine problems in-
cluding time and staff constraints (8/10), organizational and
institutional barriers (5/10), an increasing workload (4/10), or
costs or reimbursement issues (3/10).
The improvement in 2017 was evaluated for three groups:
(a) laboratories participating in both schemes who received
individual feedback (n = 76), (b) survey respondents (n =
13), and (c) workshop participants (n = 4) (Fig. 2). The num-
ber of laboratories making a genotyping error in 2017 (p =
0.036) increased significantly for returning EQA participants,
in contrast to survey respondents and workshop participants.
For those last two groups, an increase was observed in the
average genotyping score (p = 0.037) and the percentage of
laboratories obtaining the maximum score (p = 0.039),
respectively.
Discussion
Accurate biomarker tests are crucial to determine appropriate
treatment options for mCRC patients. To further improve the
standard of biomarker testing, diagnostic laboratories are en-
couraged [16, 17, 24, 25] to implement measures for continual
quality improvement, including CAPAs, education of labora-
tory personnel, and participation to EQA to compare the
laboratory’s performance to peers and identify improvement
priorities. This study focused on laboratories that reported an
error during the annual EQA assessment. It included an in-
depth analysis of EQA results to assess the influence of the
exact error causes and their follow-up on performance, which
have been reported in other fields besides molecular pathology
[15, 18–20]. It included a survey and evaluation of customized
feedback provided to the participant laboratories.
EQA participation has been shown to reflect RAS testing
performance in routine practice [14]. This was confirmed by this
study by a significant link between recurring errors and a lower
average analysis score for participants who performed less in the
first EQA scheme. This also suggests that EQA might exert a
positive influence on laboratory performance, as previously re-
ported for non-small cell lung cancer [21]. The results of this
study demonstrated 6.1% of samples misclassified in 2017.
Given the impact of the biomarker status on treatment choice
it is important to continue improving biomarker testing.
Active participation to quality improvement projects aids
laboratories in the critical evaluation of their results, as shown
by the improved performance for workshop participants and
survey respondents compared to general participants. Indeed,
protocol revisions were frequently reported as CAPAs in the
survey, and performing this CAPA type led to less errors and a
better score in the next scheme. These revisions might be
Fig. 1 Overview of performed actions according to error causes reported by survey respondents in 2016 and 2017. The size of the bubbles represents the
number of combinations between error causes and CAPAs
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technical (e.g., a change to the analysis protocol) or general of
nature (e.g., a general change to prevent errors from occurring
such as building in a second check step when entering the
results in to the online system). Moreover, the fact that the
type of action performed (instead of type of error) influences
the performance in the next scheme, suggests an active role for
laboratories in quality improvement.
Survey respondents were a good representation of EQA par-
ticipants, and error monitoring was not restricted to larger lab-
oratories, laboratories in a research setting or who are accredited
for molecular pathology. Although receiving accreditation was
not linked to a better performance in this study, it has previously
been shown to aid in the successful implementation of a new
biomarker [26]. These surveys had the advantage of a standard-
ized taxonomy, which allows to monitor error causes on a lon-
gitudinal level. The availability of multiple international labo-
ratories’ data enables to link error causes to specific laboratory
characteristics and methodologies. This can reveal systematic
shortcomings and critical points in the TTP, eventually guiding
molecular diagnostic laboratories.
In terms of continuous education, many laboratories did
not perform additional training for results interpretation be-
sides a person’s educational degree. Although training of the
staff for a specific methodology should be well documented,
and re-evaluated at frequent intervals [16], this was not
reflected in the EQA performance.
Analysis of 56.2% technical failures and 40.8% of
genotyping errors in both schemes combined, stresses the
need of risk analysis in the TTP instead of merely the analyt-
ical phase. Consistent with previous results [15, 18], the pre-
and post-analytical phases constituted a high fraction of the
observed causes. In addition, as pre-cut and pre-labeled slides
were provided to participants, an evaluation of the pre-
analytical errors in routine practice of prior steps
(deparaffinization, cutting, labeling) is advisable [27] as well
as of errors at phases outside the laboratory’s responsibility.
Namely, errors were reported in the pre-pre-analytical phase
(from test request to sample reception at the laboratory) and
the post-post-analytical phase (interpretation of the reported
results by the clinician and making the appropriate therapy
decision), albeit in other fields [15, 18–20].
This study demonstrates that pre-analytical errors were more
likely to result in not obtaining the maximum score in the next
scheme, and that a close involvement of the pathologist in results
reporting and error follow-up contributes to a better scheme per-
formance and less pre-analytical problems, especially when
using a commercial kit, in line with a previous longitudinal study
[13]. This stresses the importance for standardization of the neo-
plastic cell content determination for test outcome interpretation
inmCRC [13] (Dufraing et al., submitted for publication). This is
supported by the observation that only for 1 out of 12 cases for
which the laboratories reported that the tumor tissue was not
optimally suited for analysis in 2016, this was good practice, as
it was indeed a case without neoplastic cells. Coincidently, sur-
vey respondents in 2016 were less likely to perform the analysis
at the department of pathology and more frequently outsourced
Fig. 2 Overview of improvement between the 2016 and 2017 ESP colon
EQA schemes. *p < 0.05. Only laboratories who participated in both
EQA schemes were taken into account. Participants were awarded two
points per case for a correct outcome, resulting in a maximum genotyping
score of 20 points (23). Laboratories are considered successful if they
have a genotyping score of ≥ 90%, without major genotyping errors
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the selection of the neoplastic cell to another laboratory.
Therefore, it might be useful to analyze a larger dataset or to
evaluate non-conformities in routine practice to evaluate if these
responder characteristics might have skewed the data and if non-
conformities observed during routine reflect non-conformities
reported during EQA, as even more challenging cases might
occur in routine.
In 2017, more (analytical) methodological and personnel
errors were observed, and more frequently no CAPA was im-
plemented compared to the pre-analytical issues reported in
2016. This is surprising, as this is a requirement of the ISO
15189 and similar quality framework. Also, CAPAs were more
likely to be monitored by the laboratory director at the expense
of the laboratory technicians and were performed more often
before the official release of the EQA results. This might sug-
gest that these analytical problems are considered to be more
severe by participants as compared to pre- and post-analytical
problems in 2016, and direct follow-up may be more difficult.
Indeed, reported causes included (a) unknown factors for which
the manufacturer needed to be contacted or (b) a variant that
was not included in the method for analysis, not linked to a
specific methodology. Surprisingly, in spite of the large number
of NGS users, none of the laboratories included a bio-
informatician to interpret the results [28]. However, it must be
noted that not all survey respondents in 2016 (n = 24) registered
again in the next EQA scheme of 2017, as yearly participation
is not required to demonstrate high quality performance.
Therefore, we contacted those participants (n = 8) to ask for
the reasons of refraining from participation. Two laboratories
mentioned they only participate once every 2 years. One labo-
ratory merged with another institute and therefore stopped RAS
analyses, while another laboratory experienced bureaucratic is-
sues with the payment of the registration fee. One participant
did not agree with their awarded analysis score in 2016. The
other three laboratories did not respond.
To interpret the error rates in the EQA schemes there are
four points that need to be taken into account: (a) More sam-
ples were included containing a KRAS variant. However, no
differences were observed when re-calculating the error rates
based on the number of included samples per gene. (b) The ten
distributed samples each had a different origin. Error rates
were highest for a case containing the c.436G > A
p.(Ala146Thr) variant (15.4%, n = 123) in 2016, and for the
c.176C > A p.(Ala59Glu) variant (24.8%, n = 105) in 2017.
The reason is that laboratories may be using an analysis meth-
od which may not include all necessary codons, consistent
with previous EQA schemes [10]. (c) Many laboratories in-
correctly analyzed the sample without any neoplastic cells, for
which numbers and consequences have been previously de-
scribed [13]. (d) Pre-defined scoring criteria differed as labo-
ratories with an error in the online datasheet but correct written
report received full points in 2017 and no points in 2016.
However, this had no influence on the scores in this study.
As a conclusion, quality improvement projects such as the
study described here are important to further improve the cur-
rent high standards of biomarker testing in Europe. To avoid
any issues with testing, laboratories need to work according to
pre-defined procedures and document any changes.
Laboratories need to be aware that reporting and moni-
toring of errors is required for quality improvement. To
assure quality of biomarker analysis, it is thus clear that
a holistic approach [29] is needed at all phases in com-
bination with quality improvement projects within the
laboratory and organized by EQA providers.
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